Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03626545
Registration number
NCT03626545
Ethics application status
Date submitted
25/07/2018
Date registered
13/08/2018
Date last updated
21/08/2023
Titles & IDs
Public title
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)
Query!
Secondary ID [1]
0
0
2018-002480-26
Query!
Secondary ID [2]
0
0
CACZ885V2301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CANOPY-2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Small-Cell Lung
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Canakinumab
Treatment: Drugs - Docetaxel
Other interventions - Placebo
Experimental: Safety run-in part: Canakinumab+docetaxel - Participants were treated with full doses of docetaxel 75mg/m^2 intravenous and canakinumab 200 mg subcutaneous on Day 1 of each 21-Day cycle (dose level 1). Subjects were assessed for at least 2 complete cycles of treatment (21 days per cycle; a total of 42 days) for safety evaluation (DLT) to define RP3R. De-escalation to canakinumab 200 mg subcutaneous every 6 weeks + docetaxel 75 mg/m^2, every 3 weeks could also be considered.
Experimental: Randomized part: Canakinumab + docetaxel - Participants were treated with canakinumab subcutaneous at RP3R and docetaxel at 75 mg/m^2 every 3 weeks
Placebo Comparator: Randomized part: Placebo + docetaxel - Participants were treated with placebo subcutaneous at RP3R and docetaxel at 75 mg/m^2 every 3 weeks
Treatment: Drugs: Canakinumab
Canakinumab, 200 mg, subcutaneous. The initial dose regimen was once every 3 weeks (on Day 1 of each 21-day cycle)
Treatment: Drugs: Docetaxel
Docetaxel 75mg/m^2, intravenous, administered on Day 1 of each 21-day cycle
Other interventions: Placebo
Placebo, sub-cutaneous, admnistered at the RP3R defined in Part 1-safety run-in.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety run-in Part: Percentage of Participants With Dose Limiting Toxicities (DLTs)
Query!
Assessment method [1]
0
0
Percentage of participants with DLTs. A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 42 days of docetaxel and canakinumab treatment.
Query!
Timepoint [1]
0
0
During the first 42 days of dosing
Query!
Primary outcome [2]
0
0
Randomized Part: Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS is defined as the time from randomization to date of death due to any cause. The OS distribution was estimated using the Kaplan-Meier method and associated 95% confidence intervals were calculated for each treatment group. If a subject was not known to have died, then OS was censored at the latest date the subject was known to be alive (on or before the cut-off date).
Query!
Timepoint [2]
0
0
From randomization until death or final analysis data cutoff date (08-Jan-2021) whichever comes first (up to approximately (approx.) 18 months)
Query!
Secondary outcome [1]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. The 95% confidence intervals (CIs) were computed using Clopper and Pearson method.
CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [1]
0
0
Through final analysis data cutoff date of 08-Jan-2021 (assessed up to approx. 10 months for the safety run-in part and 18 months for the randomized part)
Query!
Secondary outcome [2]
0
0
Duration of Response (DOR)
Query!
Assessment method [2]
0
0
DOR is defined as the time from first documented response of CR or PR to date of first documented progression or death, by investigator's assessment according to RECIST 1.1 criteria. The DOR distribution was estimated using the Kaplan-Meier method and associated 95% confidence intervals were calculated for each treatment group.
CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [2]
0
0
From first documented response of CR or PR to date of first documented progression, death or final analysis data cutoff date (08-Jan-2021) whichever comes first (up to approx. 10 months for the safety run-in and 18 months for the randomized)
Query!
Secondary outcome [3]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [3]
0
0
DCR is defined as the percentage of participants with CR or PR or with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria. The 95% CIs were computed using Clopper and Pearson method.
CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Query!
Timepoint [3]
0
0
Through final analysis data cutoff date of 08-Jan-2021 (assessed up to approx. 10 months for the safety run-in part and 18 months for the randomized part)
Query!
Secondary outcome [4]
0
0
Randomized Part: Progression-Free Survival (PFS)
Query!
Assessment method [4]
0
0
PFS is defined as the time from randomization to the date of the first documented radiological progression by investigator assessment according to RECIST 1.1 response criteria or death due to any cause.
The PFS distribution was estimated using the Kaplan-Meier method and associated 95% confidence intervals were calculated for each treatment group. If a participant did not have disease progression or die at the analysis cut-off date, PFS was censored at the date of last adequate tumor assessment.
Query!
Timepoint [4]
0
0
From randomization until disease progression, death or final analysis data cutoff date (08-Jan-2021) whichever comes first (assessed up to approx. 18 months)
Query!
Secondary outcome [5]
0
0
Randomized Part: Time to Response (TTR)
Query!
Assessment method [5]
0
0
TTR is defined as the time from the date of randomization to the date of first documented response of either CR or PR, by investigator's assessment according to RECIST 1.1 criteria. The TTR distribution was estimated using the Kaplan-Meier method and associated 95% confidence intervals were calculated for each treatment group. Subjects without a confirmed CR or PR at the time of the analysis cut-off date were censored at the study-maximum follow-up time for subjects with a PFS event (i.e., disease progression or death due to any cause), or at the date of the last adequate tumor assessment for subjects without a PFS event.
CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [5]
0
0
From randomization until first documented response or final analysis data cutoff date (08-Jan-2021) whichever comes first (up to approx. 18 months)
Query!
Secondary outcome [6]
0
0
Randomized Part: Time to Definitive 10-point Deterioration (TTD) Symptom Scores of Chest Pain, Cough and Dyspnea Per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) Lung Cancer (LC13) Questionnaire
Query!
Assessment method [6]
0
0
The EORTC QLQ-LC13 comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, dyspnea, and chest pain) and treatment-related symptoms from conventional chemotherapy and radiotherapy (ie. hair loss, neuropathy, sore mouth, and dysphagia). Scores for each scale and single-item range from 0 to 100, with higher scores indicating higher level of symptoms. TTD for chest pain, cough and dyspnea is defined as the time from randomization to the date of event, which is defined as at least 10 points absolute worsening from baseline of the corresponding scale score, with no later change below this threshold ie.<10 points was observed or if this worsening was observed at the last assessment for the subject, or death due to any cause (whichever occurs earlier). If a subject did not have an event, TTD was censored at the last adequate assessment.
Query!
Timepoint [6]
0
0
From baseline through final analysis data cutoff date of 08-Jan-2021 (assessed up to approx. 18 months)
Query!
Secondary outcome [7]
0
0
Randomized Part: Time to Definitive 10-point Deterioration in Global Health Status (GHS)/Quality of Life (QoL), Shortness of Breath and Pain Per EORTC QLQ-C30 Questionnaire
Query!
Assessment method [7]
0
0
The EORTC QLQ-C30 includes 5 functional scales (physical,role,cognitive,emotional and social), 3 symptom scales (fatigue,pain and nausea/vomiting), a GHS/QoL scale, and 6 single items (constipation,diarrhea,insomnia,shortness of breath,appetite loss and financial difficulties). For each scale and single-item, scores range between 0 and 100. A high score for functional scales/ GHS/QoL represents better functioning or QoL, a high score for symptom scales/single items represents significant symptomatology. TTD in GHS/QoL, shortness of breath and pain is defined as the time from randomization to the date of event, defined as at least 10 points absolute worsening from baseline of the corresponding scale score, with no later change below this threshold i.e.<10 points was observed or if this worsening was observed at the last assessment for the subject, or death due to any cause (whichever occurs earlier). If a subject did not have an event, TTD was censored at the last adequate assessment.
Query!
Timepoint [7]
0
0
From baseline through final analysis data cutoff date of 08-Jan-2021 (assessed up to approx. 18 months)
Query!
Secondary outcome [8]
0
0
Randomized Part: Change From Baseline in GHS/QoL, Shortness of Breath and Pain Scores as Per the EORTC QLQ C30 Questionnaire
Query!
Assessment method [8]
0
0
The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and 6 single items (constipation, diarrhea, insomnia, dyspnoea, appetite loss and financial difficulties). For each scale and item, scores range 0-100. A high score for functional scales/QoL represents better functioning/QoL; a high score for symptom scales and items represents significant symptomatology. Changes from baseline in QoL, shortness of breath and pain scores are presented. For QoL, a negative change from baseline indicates improvement; for shortness of breath and pain a positive change from baseline indicates improvement. For subjects who discontinued treatment without disease progression, post-treatment efficacy visits 1, 2, 3 and 5 were conducted every 6 weeks (for the first 12 months since start of treatment) and every 12 weeks (after 12 months since start of treatment) until disease progression
Query!
Timepoint [8]
0
0
Baseline, every 3 weeks from Week 3 until end of treatment, every 6 or 12 weeks post-treatment until progression (post-treatment efficacy visits), 7 and 28 days post progression through final analysis cutoff date of 08Jan2021 (up to approx. 18 months)
Query!
Secondary outcome [9]
0
0
Randomized Part: Change From Baseline in Chest Pain, Cough and Dyspnea Scores as Per the EORTC-QLQ LC13 Questionnaire
Query!
Assessment method [9]
0
0
The EORTC QLQ-LC13 is a 13-item questionnaire. It comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, dyspnea, and chest pain) and treatment-related symptoms from conventional chemotherapy and radiotherapy (ie, hair loss, neuropathy, sore mouth, and dysphagia). Scores for each scale and single-item range from 0 to 100, with higher scores indicating higher ("worse") level of symptoms. Changes from baseline in chest pain, cough and dyspnea scores are presented. A positive change from baseline indicates improvement. For subjects who discontinued treatment without disease progression, post-treatment efficacy visits 1, 2, 3 and 5 were conducted every 6 weeks (for the first 12 months since start of treatment) and every 12 weeks (after 12 months since start of treatment) until disease progression
Query!
Timepoint [9]
0
0
Baseline, every 3 weeks from Week 3 until end of treatment, every 6 or 12 weeks post-treatment until progression (post-treatment efficacy visits), 7 and 28 days post progression through final analysis cutoff date of 08Jan2021 (up to approx. 18 months)
Query!
Secondary outcome [10]
0
0
Randomized Part: Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Health State Scores
Query!
Assessment method [10]
0
0
The EQ-5D-5L descriptive system provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of these dimensions, the participant self-assigned a score: from 1 (no problems) to 5 (extreme problems). The 5 digit health states obtained for each dimension was converted into a single mean index value based on the EQ-5D crosswalk value set for the UK using the time trade-off method. This index ranges from -0.594 (worst health) to 1.0 (best health). A positive change from baseline indicates improvement. For subjects who discontinued treatment without disease progression, post-treatment efficacy visits 1, 2, 3 and 5 were conducted every 6 weeks (for the first 12 months since start of treatment) and every 12 weeks (after 12 months since start of treatment) until disease progression
Query!
Timepoint [10]
0
0
Baseline, every 3 weeks from Week 3 until end of treatment, every 6 or 12 weeks post-treatment until progression (post-treatment efficacy visits), 7 and 28 days post progression through final analysis cutoff date of 08Jan2021 (up to approx. 18 months)
Query!
Secondary outcome [11]
0
0
Safety run-in Part: Maximum Plasma Concentration (Cmax) of Canakinumab
Query!
Assessment method [11]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. Cmax of canakinumab was calculated from canakinumab plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [11]
0
0
Cycle 1 Day 1 at pre-dose and end of infusion and 24, 48, 168 and 336 hours (h) post-infusion. Each cycle is 21 days
Query!
Secondary outcome [12]
0
0
Safety run-in Part: Time of Maximum Plasma Concentration (Tmax) of Canakinumab
Query!
Assessment method [12]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. Tmax of canakinumab was calculated from canakinumab plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Actual recorded sampling times were considered for the calculations.
Query!
Timepoint [12]
0
0
Cycle 1 Day 1 at pre-dose and end of infusion and 24, 48, 168 and 336 hours (h) post-infusion. Each cycle is 21 days
Query!
Secondary outcome [13]
0
0
Safety run-in Part: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Canakinumab
Query!
Assessment method [13]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. AUClast of canakinumab was calculated from canakinumab plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [13]
0
0
Cycle 1 Day 1 at pre-dose and end of infusion and 24, 48, 168 and 336 hours (h) post-infusion. Each cycle is 21 days
Query!
Secondary outcome [14]
0
0
Safety run-in Part: Cmax of Docetaxel
Query!
Assessment method [14]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. Cmax of docetaxel was calculated from docetaxel plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [14]
0
0
Cycle 1 Day 1 and Cycle 2 Day 1 at pre-infusion, end of infusion, and 2, 4, 6 and 8 hours post-dose. Each cycle is 21 days
Query!
Secondary outcome [15]
0
0
Safety run-in Part: Tmax of Docetaxel
Query!
Assessment method [15]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. Tmax of docetaxel was calculated from docetaxel plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Actual recorded sampling times were considered for the calculations.
Query!
Timepoint [15]
0
0
Cycle 1 Day 1 and Cycle 2 Day 1 at pre-infusion, end of infusion, and 2, 4, 6 and 8 hours post-dose. Each cycle is 21 days
Query!
Secondary outcome [16]
0
0
Safety run-in Part: AUClast of Docetaxel
Query!
Assessment method [16]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. AUClast of docetaxel was calculated from docetaxel plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [16]
0
0
Cycle 1 Day 1 and Cycle 2 Day 1 at pre-infusion, end of infusion, and 2, 4, 6 and 8 hours post-dose. Each cycle is 21 days
Query!
Secondary outcome [17]
0
0
Randomized Part: Pre-dose Plasma Trough Concentration (CTrough) of Canakinumab
Query!
Assessment method [17]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. CTrough of canakinumab was calculated from canakinumab plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [17]
0
0
Pre-dose on Cycle 1 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1 and Cycle 18 Day 1. Each cycle is 21 days.
Query!
Secondary outcome [18]
0
0
Randomized Part: Cmax of Docetaxel
Query!
Assessment method [18]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. Cmax of docetaxel was calculated from docetaxel plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [18]
0
0
Cycle 1 Day 1 and Cycle 4 Day 1 at pre-infusion, end of infusion, and 2, 4 and 6 hours post-dose. Each cycle is 21 days
Query!
Secondary outcome [19]
0
0
Randomized Part: Tmax of Docetaxel
Query!
Assessment method [19]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. Tmax of docetaxel was calculated from docetaxel plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Actual recorded sampling times were considered for the calculations.
Query!
Timepoint [19]
0
0
Cycle 1 Day 1 and Cycle 4 Day 1 at pre-infusion, end of infusion, and 2, 4 and 6 hours post-dose. Each cycle is 21 days
Query!
Secondary outcome [20]
0
0
Randomized Part: AUClast of Docetaxel
Query!
Assessment method [20]
0
0
Venous whole blood samples were collected for pharmacokinetics characterization. AUClast of docetaxel was calculated from docetaxel plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Query!
Timepoint [20]
0
0
Cycle 1 Day 1 and Cycle 4 Day 1 at pre-infusion, end of infusion, and 2, 4 and 6 hours post-dose. Each cycle is 21 days
Query!
Secondary outcome [21]
0
0
Randomized Part: Canakinumab Antidrug Antibodies (ADA) at Baseline
Query!
Assessment method [21]
0
0
ADA prevalence at baseline was calculated as the percentage of participants who had an ADA positive result at baseline
Query!
Timepoint [21]
0
0
Baseline
Query!
Secondary outcome [22]
0
0
Randomized Part: Canakinumab ADA Incidence On-treatment
Query!
Assessment method [22]
0
0
ADA incidence on-treatment was calculated as the percentage of participants who were treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)
Query!
Timepoint [22]
0
0
Pre-dose at Cycle 1 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1 , end of treatment, and 130 days after end of treatment through final analysis data cutoff date of 08-Jan-2021 (assessed up to 18 months). Each cycle is 21 days
Query!
Eligibility
Key inclusion criteria
Key
- Histologically confirmed advanced (stage IIIB) or metastatic NSCLC.
- Subject had received one prior platinum-based chemotherapy and one prior PD-(L)1
inhibitor therapy for locally advanced or metastatic disease.
- Subject with ECOG performance status (PS) of 0 or 1.
- Subject with at least 1 evaluable (measurable or non-measurable) lesion by RECIST 1.1
in solid tumors criteria.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subject who previously received docetaxel, canakinumab (or another IL-1ß inhibitor),
or any systemic therapy for their locally advanced or metastatic NSCLC other than one
platinum-based chemotherapy and one prior PD-(L)1 inhibitor.
- Subject with EGFRor ALK positive tumor.
- History of severe hypersensitivity reaction to monoclonal antibodies, taxanes or
excipients of docetaxel or canakinumab.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/01/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
20/12/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
245
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Greenslopes
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Shepparton
Query!
Recruitment postcode(s) [1]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [2]
0
0
3630 - Shepparton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Missouri
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Ohio
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Utah
Query!
Country [7]
0
0
Argentina
Query!
State/province [7]
0
0
Buenos Aires
Query!
Country [8]
0
0
Argentina
Query!
State/province [8]
0
0
La Rioja
Query!
Country [9]
0
0
Argentina
Query!
State/province [9]
0
0
Santiago del Estero
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Oost Vlaanderen
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Bruxelles
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Charleroi
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Gent
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Roeselare
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
BA
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
RS
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
SC
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
British Columbia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Chile
Query!
State/province [20]
0
0
Santiago
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Sichuan
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Shanghai
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Brno - Bohunice
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Ostrava Vitkovice
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
Herlev
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Odense C
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Cedex 09
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Besancon Cedex
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Bordeaux Cedex
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Bron
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Strasbourg Cedex
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Berlin
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Dresden
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Frankfurt
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Gerlingen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Grosshansdorf
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Koeln
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Ulm
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Heraklion Crete
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Thessaloniki
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Pest
Query!
Country [42]
0
0
Israel
Query!
State/province [42]
0
0
Ramat Gan
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
LU
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
MI
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
PN
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Aichi
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Hyogo
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Kanagawa
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Tokyo
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Osaka
Query!
Country [51]
0
0
Jordan
Query!
State/province [51]
0
0
Amman
Query!
Country [52]
0
0
Korea, Republic of
Query!
State/province [52]
0
0
Seocho Gu
Query!
Country [53]
0
0
Korea, Republic of
Query!
State/province [53]
0
0
Seoul
Query!
Country [54]
0
0
Lebanon
Query!
State/province [54]
0
0
Ashrafieh
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Amsterdam
Query!
Country [56]
0
0
Netherlands
Query!
State/province [56]
0
0
Groningen
Query!
Country [57]
0
0
Netherlands
Query!
State/province [57]
0
0
Maastricht
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Gdansk
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Rzeszow
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Warszawa
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Pushkin Saint Petersburg
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
St Petersburg
Query!
Country [63]
0
0
Singapore
Query!
State/province [63]
0
0
Singapore
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Andalucia
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Catalunya
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Comunidad Valenciana
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Galicia
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Madrid
Query!
Country [69]
0
0
Taiwan
Query!
State/province [69]
0
0
Tainan
Query!
Country [70]
0
0
Taiwan
Query!
State/province [70]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study was designed to evaluate the role of canakinumab in combination with docetaxel in
subjects with advanced non-small cell lung cancer (NSCLC) previously treated with PD-(L)1
inhibitors and platinum-based chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03626545
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03626545
Download to PDF